Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026)
Anaptysbio (ANAB) reported Depreciation & Amortization (CF) of $130000.0 for Q1 2026, down 10.96% on a YoY basis from $146000.0 in Q1 2025, and down 0.76% quarter-over-quarter from $131000.0 in Q4 2025.
Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Anaptysbio has reported Depreciation & Amortization (CF) for 11 years, with the latest figure at $130000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 10.96% year-over-year to $130000.0; the trailing twelve-month figure through Mar 2026 stood at $543000.0 (down 7.81% YoY), and the FY2025 full-year result was $559000.0, down 7.76% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $130000.0, down from $131000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $184000.0 in Q4 2022, with the low at $130000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $154235.3 across 5 years, with a median of $158000.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) grew 29.6% — and 2024, when it retreated 12.12%.
- Anaptysbio's Depreciation & Amortization (CF) stood at $184000.0 in 2022, then declined by 10.33% to $165000.0 in 2023, then dropped by 12.12% to $145000.0 in 2024, then dropped by 9.66% to $131000.0 in 2025, then slipped by 0.76% to $130000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $130000.0 (Q1 2026), $131000.0 (Q4 2025), and $140000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |